The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.17 — safe zoneOK
- Earnings-manipulation signal · Beneish M -3.42 — no flag raisedOK
- Earnings quality 60/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Moderna, Inc. reports it. History and quarterly detail are in the app.
- Net product sales$1.8B
- COVID$1.8B
- Other revenue$126.0M
- Stand-ready manufacturing revenue$80.0M
- Grant revenue$22.0M
Leadership changes
From Moderna, Inc.'s own filings, the day they're filed.
- Abbas Hussain · Chief Executive Officer · appointmenteff. 2024-10-02
- David M. Rubenstein · Chairman · appointmenteff. 2024-08-05
- Robert Langer · Directors · departureeff. 2024-08-05
Latest filings
- 8-K · Company announcement2026-05-11
- 8-K · Company announcement2026-05-01
- 10-Q · Quarterly report2026-05-01
- DEF 14A · Annual proxy (pay & governance)2026-03-16
- 8-K · Company announcement2026-03-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Moderna, Inc., every answer cited🔒
- The Intelligence Brief — added when Moderna, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.